Recent Updates
Recently added Catalysts
CORT Negative Sentiment Score: 30/100

Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Key Takeaway: Corcept Therapeutics Inc. is facing a securities class action lawsuit linked to its failure to disclose vital information regarding its drug relacorilant during the Class Period. The lawsuit was triggered after the FDA issued a Complete Response Letter stating additional evidence was necessary for the drug's approval. As a result, Corcept's stock value plummeted by over 50% following this announcement. Investors who suffered losses during this time have until April 21, 2026, to file lead plaintiff applications.

Market Sentiment Analysis

CONCERNS & RISKS

  • Corcept Therapeutics faced a significant stock price decline of over 50%.
  • The FDA issued a Complete Response Letter, indicating further evidence of effectiveness is needed for approval.
  • The company and its executives are accused of failing to disclose crucial information during a critical period.

Full Press Release Details

NEW YORK and NEW ORLEANS, March 31, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) (“Corcept” or the “Company”), if they purchased or otherwise acquired the Company’s shares between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
If you purchased shares of Corcept and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqcm-cort/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by April 21, 2026.
Corcept and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The complaint alleges that, during the Class Period, the Company represented to investors that there was a high likelihood that one of its lead new product candidates, relacorilant, would receive approval from the U.S. Food and Drug Administration (“FDA”) after the Company’s New Drug Application (“NDA”) submission. However, on December 31, 2025, the Company disclosed that the FDA had issued a Complete Response Letter (“CRL”) regarding the NDA for relacorilant and that it had “concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.”
On this news, the price of Corcept’s shares plummeted by $35.40 per share, or 50.4%, from a closing price of $70.20 on December 30, 2025, to a closing price of $34.80 on December 31, 2025.
The case is Allegheny County Employees’ Retirement System v. Corcept Therapeutics Incorporated, No. 26-cv-01525.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.
TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services
To learn more about KSF, you may visit www.ksfcounsel.com.
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
1100 Poydras St., Suite 960
New Orleans, LA 70163
CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

Tags

Securities Litigation

Frequently Asked Questions

What is the deadline to file for lead plaintiff in Corcept's case?

Investors must file lead plaintiff applications by April 21, 2026.

What alleged violations does Corcept face in the lawsuit?

Corcept is accused of not disclosing key information, violating federal securities laws.

How much did Corcept's share price drop after the FDA announcement?

Corcept's share price dropped by $35.40, or 50.4% on December 31, 2025.

Who can investors contact for more information about the case?

Investors can contact Lewis Kahn at KSF by phone or email for case details.

What was the reason for the FDA's Complete Response Letter to Corcept?

The FDA needed more evidence of effectiveness for Corcept's product, relacorilant.

Last updated: Apr 1, 2026